Cannara Biotech Archives - Green Market Report

StaffJuly 27, 2023
Daily-Hit-Header.png

5min00

The Daily Hit is a recap of the top financial news stories for July 27, 2023.

On the Site

Mastercard Fallout Means More Pain for Cannabis Industry

When financial titan Mastercard Inc. (NYSE: MA) cut ties with a swath of payment processors that had been aiding marijuana retailers across the country, the news sent shivers down the collective spine of the cannabis industry. Analysts predicted the move would only increase the likelihood of all-cash transactions, thus heightening the chances of more violent robberies. Read more here.

Tilray Leverages CPG Expertise to Build Beyond Cannabis

Against the backdrop of a tumbling sector, Tilray’s fourth-quarter and full-year financial results for 2023 were dynamite. The company reported better-than-expected top-line results across all segments. The adult-use cannabis segment recorded its best revenue generation in nearly eight quarters despite the challenges of price deflation. Read more here.

Michigan Cannabis Companies Wanted a Crackdown on Unlicensed Cannabis – They Got It, and Then Some

After years of little to no enforcement under former Michigan Cannabis Regulatory Agency Executive Director Andrew Brisbo, operators demanded a change. They wanted regulators to root out the illicit market marijuana entering the legal space and cratering prices and to also punish those involved in the schemes. The industry is now crying foul and is urging the agency to slow down fines and apply them more evenly under sustained pricing pressure. Read more here.

Imperial Brands to Retain Cannabis Investment as Auxly Extends Debenture Maturity

Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF) has announced a two-year extension to the maturity date of a $123 million debenture held by its partner, Imperial Brands PLC. The loan, originally due in September 2024, will now mature in September 2026. Read more here.

Cannara Biotech Delivers Solid Quarter as Company Grows

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) announced its fiscal third quarter 2023 financial and operating results for the third quarter ending May 31, 2023. Cannara Biotech reported revenue of $15.8 million versus last year’s $9.9 million for the same time period. The company also reported net income of $2.9 million versus last year’s net income of $1.4 million in the same time period. Read more here.

In Other News

Tantalus Labs

A B.C. Supreme Court judge has approved the bulk sale of more than 1.2 tonnes of cannabis by a company after the Canada Revenue Agency threatened to destroy it. In a ruling released online this week, the court allowed Tantalus Labs Ltd. to move ahead with a hasty sale of its remaining inventory of cannabis flower. The agency had earlier declined to renew the company’s excise tax license due to financial difficulties. Read more here.

Missouri

Regulators at the Missouri Department of Health and Senior Services have had trouble holding medical-marijuana businesses accountable for things that went against their rules. But when new cannabis regulations go into effect on Sunday, officials will have that power to hit marijuana facilities with fines, suspend their operations or even revoke their licenses if they host events where unlawful activity occurs. Read more here.


Debra BorchardtJuly 27, 2023
Cannara.jpg

5min00

Cannara Biotech Inc.  (TSXV: LOVE) (OTCQB: LOVFF) announced its fiscal third quarter 2023 financial and operating results for the third quarter ending May 31, 2023. Cannara Biotech reported revenue of $15.8 million versus last year’s $9.9 million for the same time period. The company also reported net income of $2.9 million versus last year’s net income of $1.4 million in the same time period.

“This past quarter was a tremendous success as Cannara grew its market share by more than 30% in Quebec (7%1 to 9.3%2) and in Ontario (2%3 to 2.7%4), along with growing sales in BC and the commencement of sales in a new market, Alberta, the second largest cannabis market in Canada.  With the firm’s robust and innovative pipeline leading the way, SKU listings rising and an additional three 25,000 square feet growing zones activated this year, revenues, gross profits, EBITDA, and net income all increased, paving the way for sustained growth moving forward,” said Zohar Krivorot, President & Chief Executive Officer of Cannara. “The response in the consumer market for our premium, high-quality yet affordable cannabis products has been tremendous since inception, and we expect to continue to grow market share across all provinces as we continue to introduce new and innovative products to our customers across Canada.”

Growing Company

Cannara reported that its free cash flow in the quarter increased 113% to $3.2 million from $1.5 million last year. Free cash flow increased by 68% sequentially from $1.9 million in the second quarter to $3.2 million in the third. The company said it has $27.1 million in working capital as of May 31, 2023, which includes $4 million of cash on hand and $10 million in accounts receivable.

Nicholas Sosiak, Chief Financial Officer of Cannara said, “Our ninth consecutive quarter of positive Adjusted EBITDA in addition to positive net income was the culmination of innovation and hard work, improved capacity utilization, improved efficiencies and increased demand for Cannara’s’ products across all markets.  The initial response in the Alberta market has been spectacular, and we are excited to increase our footprint in this vibrant, growing market, with the imminent listing of 16 additional SKUs for the Alberta consumer by next month.  The company’s stated goal of expanding cultivation capacity by 50% by year-end was achieved three months ahead of schedule and we continue to execute on our strategy of increasing our production capacity in line with growing demand.”

Cannara is growing at a time when many cannabis companies are shrinking. The company activated its 9th of 24 individual 25,000 square foot growing zones at its Valleyfield Facility, a 50% capacity increase at the Valleyfield Facility compared to the previous fiscal year-end, reaching a total of 225,000 square feet of active canopy. Combined with its Farnham Facility, the Company’s current annual production capacity is approximately 30,500 kg of premium-grade cannabis per year, which will increase up to 100,000 kg per year when the Valleyfield Facility is fully built out.

In addition to the increased cultivation space, Cannara increased its employee headcount from 210 employees to 270 employees in the quarter. The company said this was a 29% increase to support operational growth.

Cannara Biotech is a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft.


StaffApril 24, 2023
daily-hit.jpg

5min00

The Daily Hit is a recap of the top financial news stories for April 24, 2023.

On the Site

SNDL Delivers Uneven Earnings: Big Revenue Gain, Big Losses

SNDL Inc. (Nasdaq: SNDL) reported its earnings in Canadian dollars for the full year and fourth quarter ended Dec. 31, 2022. Net revenue for the quarter was $240.4 million, an increase of 4% over the third quarter of 2022, with sequential growth in liquor retail, cannabis retail, and cannabis operations segments. Read more here.

Detroit Businessman Pleads Guilty to Bribing Marijuana Regulator

A Detroit-area businessman who pleaded guilty Friday to bribing a top medical marijuana regulator in exchange for approval of state dispensary licenses said the payments included $4,000 a month for the official’s wife, who was paid as a “consultant” during the process. Read more here.

TILT Holdings Sees More C-Suite Shuffle, Gary Santo Departs CEO Role

Phoenix-based TILT Holdings Inc. (NEO: TILT) (OTCQX: TLLTF) announced a change in its top leadership. Gary Santo has resigned as the chief executive officer and board member, effective immediately. Tim Conder, a board member, has been appointed as the interim CEO. Read more here.

SC Labs Snaps Up C4 Labs Arizona

SC Labs, a U.S. cannabis and hemp testing company, has acquired Arizona-based C4 Laboratories for an undisclosed price. In a Monday statement, SC Labs said that the acquisition allows the company to expand its reach to the Arizona market, bringing the total number of states where the company is licensed and accredited to five: Arizona, California, Colorado, Michigan, and Oregon. Read more here.

Cannara Biotech Revenues Rise as Expansion Brings in More Profit

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) posted meaningful rises in net revenues for its fiscal second quarter results ending Feb. 28. The vertically integrated Canadian producer reported a 76% revenue increase, reaching $13 million, compared to the same period last year. The increase is attributed to the company’s expanding workforce and increased growing capacity. Read more here.

In Other News

Blueberries Medical Corp.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S., reported revenue for the year ended Dec. 31, 2022, of $235,449, an increase of $96,702 (or 70%) from comparative period. The increase is primarily due to the introduction of the new product CBD isolate. Read more here.

NuProject

Colorado Gov. Jared Polis and the Cannabis Business Office within the Colorado Office of Economic Development & International Trade announced the Cannabis Business Loan Program for social equity licensed cannabis businesses in Colorado. The CBO has partnered with mission-based lender NuProject to provide financing that is not otherwise available to cannabis businesses through traditional lenders. Read more here.

Aurora Cannabis

Aurora Cannabis Inc. (Nasdaq: ACB) (TSX: ACB) repurchased an aggregate of approximately $22.3 million (US$16.6 million) principal amount of its convertible senior notes in multiple transactions since the start of April 2023 at a total cash cost, including accrued interest, of $16.7 million and $5.3 million (US$4.0 million), including accrued interest, satisfied by the issuance of an aggregate ~6.35 million common shares of Aurora. Read more here.


StaffJanuary 24, 2023
daily-hit.jpg

4min00

The Daily Hit is a recap of the top financial news stories for January 24, 2023.

On the Site

FDA Releases Cannabis Industry Research Guidance

The guidance document from the U.S. Food and Drug Administration follows the 2018 federal legalization of hemp via that year’s federal farm bill, which removed cannabis with less than 0.3% THC by dry weight from the list of controlled substances. Read more here.

Mississippi Medical Marijuana Sales May Start Friday

But over the weekend, state regulators began activating patient cards and notifying cardholders, so they could visit dispensaries and get the rest of mandated info uploaded to the state in advance of the sales launch. Read more here.

SMACKED Social Equity Dispensary Opens in NYC

New York’s first social equity applicant dispensary opened its doors today. Roland Conner, the owner of SMACKED Village located in Greenwich Villag, had been incarcerated for cannabis but prefers to be called an entrepreneur, not an ex-con. Watch video from the opening event here.

Cannara Biotech Expands, But Makes Just $2,200 in Q1 2023

Montreal-based Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) was slightly profitable for its first financial quarter of 2023, with $2,209 in net income against $7.7 million in revenue, the company reported. The vertically integrated Canadian marijuana company also spent $2.7 million to expand its footprint, increase headcount, and bring 14 new product lines to market during the quarter, which ended Nov. 30 last year. Read more here.

In Other News

22nd Century Group

22nd Century Group, Inc. (Nasdaq: XXII), a biotechnology company dedicated to improving health with reduced-nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, acquired privately held RX Pharmatech Ltd (RXP), a United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K. Food Standards Agency (FSA). Terms of the agreement include an up-front payment of $650,000 in cash and stock and a three-year equity earn-out based on revenue milestones. Read more here.

Curaleaf

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) announced the expansion of its Grassroots brand in New Jersey with the launch of premium cannabis flower and pre-rolls. Available now at all Curaleaf locations across the state, New Jersey is the eighth market to offer Grassroots products. Read more here.


John SchroyerJanuary 24, 2023
Cannara.jpg

2min00

Montreal-based Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) was slightly profitable for its first financial quarter of 2023, with $2,209 in net income against $7.7 million in revenue, the company reported.

The vertically integrated Canadian marijuana company also spent $2.7 million to expand its footprint, increase headcount, and bring 14 new product lines to market during the quarter, which ended Nov. 30 last year. The quarter was the second in a row in which Cannara turned a profit, according to a news release.

“We continued to execute on Cannara’s growth plan,” said CEO Zohar Krivorot in the release, lauding the “hard work” of company employees.

Revenues were up 57% year-over-year. Cannara also bucked the layoff trend, increasing its staffing levels from 190 workers a year prior to 280 employees in the latest quarter

In addition, Cannara expanded its cultivation footprint by opening a new Valleyfield facility, the seventh of 24 planned grow operations, which will have 25,000 square feet of canopy apiece. That brings Cannara’s cultivation capacity to 175,000 square feet, and two more facilities are already in the works.

The company also entered the British Columbia market, while maintaining its market share in other provinces, and is poised to enter the Alberta market as well.


Adam JacksonNovember 28, 2022
Cannara.jpg

7min00

Canadian mega-producer Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) posted positive results that illustrate the company’s efficiency amid a crowded supply side market and pinching margins. The Québec-based operator released its fourth quarter and fiscal year 2022 financial results for the three-month and full year periods ending August 31.

Cannara reported C$12 million in revenue, an 84% increase versus the fourth quarter last year and a 19% rise from the previous quarter. The company brought in C$36 million worth of revenue for the 2022 fiscal year, a 108% increase rise versus 2021’s annual financials.

Cannara saw a net income of C$2.6 million for the fourth quarter and C$2.3 million for the 2022 fiscal year.

“This past year was a tremendous success, and I am very proud of the team at Cannara for their dedication, hard work and support as we continue to strive towards being one of the premier cannabis cultivators in the country,” said CEO and president Zohar Krivorot.

Cannara posted a gross profit before fair value adjustments of C$4.8 million, an increase of 38% versus the same time last year and a 27% increase from the previous quarter.

CFO Nicholas Sosiak touted the company’s sixth straight quarter of positive adjusted EBITDA, which came out to C$2.5 million, an 83% increase versus the fourth quarter last year. Adjusted EBITDA was C$5.3 million for the fiscal year 2022, a 254% rise vs fiscal year 2021.

“Revenues, profits, and net income have all increased over the past 12 months while simultaneously adding new products for our customer base and none of this would be possible without the hard work of the entire Cannara family,” said Sosiak. “Over the last twelve months, we have achieved a ramp-up in production which was necessary to support the recent expansion plans to the other provinces.”

The company said it moved around 26% more kilograms of cannabis since the previous period, with 2,570 kg or 730,000 units sold across 3 flagship brands during the fourth quarter.

The increase in production coming from the company’s new Valleyfield Facility, which came online by the second half of the year, provided a boon for the company, with the number of kgs sold rising by 69% versus the first half of the year.

Around 7,300 kg of cannabis or 2 million units sold during the fiscal year, an increase of approximately 1.5 million of units sold or 286% versus the fiscal year in 2021.

“Our state-of-the-art Valleyfield Facility is producing, as of today, seven of its twenty-four growing zones, each containing 9,600 plants each,” said Krivorot. We remain confident in fulfilling the remaining grow zones over the coming quarters, and our successful harvests should shed any doubt regarding our ability to achieve all of our expansion milestones and bring more premium-grade cannabis to market.”

Cannara said it has C$29 million in working capital as of August 31.

Taking it to the bank

The company said in December that it planned to optimize additional debt financing from CIBC to finalize the redesign of several zones at the Valleyfield Facility as a way to replicate the indoor cultivation environment, including growing without utilizing the sun and launching the operations at the site – all while leveraging Québec’s low electricity costs.

Following the report, the company intends to fashion its long-term goals with the help of a C$50 million credit facility secured by BMO Commercial Banking. The credit facility includes a three-year term loan for C$39.3 million with an accordion for up to an additional C$10 million, a C$5 million line of credit, and C$5.7 million for the issuance of a letter of credit. Funding was received after the quarter-end in May.

In June, Cannara used part of the C$39.3 million from that term loan to repay the existing C$21.8 million loan with CIBC and $5.7 million for the issuance of a letter of credit to cover certain deposit requirements. The company also granted a total of 600,000 stock options to employees and 613,333 stock options to consultants at an exercise price of C$0.18.

Sosiak said last quarter that the credit facility gives the company the “necessary liquidity” to continue its expansion, adding that the financial resources would help drive capital investment at the Valleyfield Facility and its cannabis supply in a way that allows the company to offer premium products “market-disrupting” price points.


Adam JacksonJuly 27, 2022
Cannara.jpg

7min00

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) posted positive third-quarter results – showing the resilience of the Québec mega-producer amid waning profits for many throughout the sector. The company announced its third-quarter financial and operating results for the three and nine-month periods ending May 31, 2022.

For the key metric of quarterly revenue, Cannara saw a 36% gain of $10.1 million – a record high – since the previous quarter, and 41% increase since this time last year at $24.1 million in year-to-date revenue. The company also delivered a positive net income of $1.4 million for the quarter.

CEO Zohar Krivorot said, “We continue to be ahead of schedule on all of our stated objectives for this year while at the same time delivering record revenue, our fifth positive quarter of Adjusted EBITDA, and positive net income.”

The company also posted its fifth consecutive quarter of positive adjusted EBITDA of $1.8M with a net income of $1.4 million, up from an adjusted EBITDA of $34,000 in the previous quarter. The gains represent $2.8 million for the first nine months of 2022 compared to $139,000 of adjusted EBITDA for the first nine months of 2021, “all while continuing to support over $700,000 in one-time startup expenses for the Valleyfield Facility,” the release said.

Valleyfield

Approximately 4,800 kg of cannabis or 1,286,000 units were sold across three flagship brands during the nine-month period of 2022, an increase of over 1 million units sold compared to the same period last year. The company also invested $4.9 million in capital expenditures during the quarter and over $12 million during the nine-month period, the bulk of the capital expenditures related to the finalization of the construction of the Valleyfield facility. Cannara has $13 million in working capital as of May 31, 2022.

“We are also pleased to report to shareholders that our new state-of-the-art Valleyfield Facility, as of today, is producing six out of its twenty-four growing zones, each containing 9,600 plants,” said Krivorot. “We have multiple successful harvests delivered from our new facility, which provides us confidence in our ability to continue our expansion and to grow consistent premium-grade cannabis at scale.”

Benefits of Banking Access

Cannara said in December that it planned to optimize additional debt financing from CIBC to finalize the redesign of several zones at the Valleyfield Facility as a way to replicate the indoor cultivation environment, including growing without utilizing the sun and launching the operations at the site – all while leveraging Québec’s low electricity costs.

Following the report, the company intends to fashion its long-term goals with the help of a $50 million credit facility secured by BMO Commercial Banking. The credit facility includes a three-year term loan for $39.3 million with an accordion for up to an additional $10 million, a $5 million line of credit, and $5.7 million for the issuance of a letter of credit. Funding was received after the quarter-end in May.

In June, Cannara used part of the $39.3 million from that term loan to repay the existing $21.8 million loan with CIBC and $5.7 million for the issuance of a letter of credit to cover certain deposit requirements. The company also granted a total of 600,000 stock options to employees and 613,333 stock options to consultants at an exercise price of $0.18.

“The credit facility provides the company with the necessary liquidity to continue to execute on our expansion plans,” said CFO Nicholas Sosiak. “These additional resources will assist Cannara to increase its cannabis supply through capital investment at the Valleyfield Facility with a continued focus on providing consumers with premium products at sustainable, market-disrupting high value propositions.”

Sosiak said the strategy helps the company increase market share while simultaneously entering new provinces.

“Given that Cannara only operates today in 2 major Canadian markets,” he said, “I am really excited for the Company’s long-term picture as we have plenty of room for growth.”

Cannara is a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today. The company now has six of its 24 growing zones in full production, representing 150,000 square feet of canopy holding over 55,000 plants that can be harvested four times per year.

 


Debra BorchardtDecember 8, 2021
Cannara.jpg

6min00

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) announced its fourth quarter and fiscal year 2021 financial results for the ending on August 31, 2021. Cannara reported total revenue of $6.5 million for the fourth fiscal quarter, an increase of $5.9 million from $0.6 million in the fourth quarter of 2020. The company also delivered a net income of $1.1 million, an increase of $5.0 million from a net loss of $3.9 million in the fourth quarter of 2020. The adjusted EBITDA amounted to $1.4 million, an increase of $2.8 million from a negative adjusted EBITDA of $1.4 million in the fourth quarter of 2020.

For the full fiscal year of 2021 Cannara reported total revenue of $17.3 million, an increase of $14.7 million while the net loss amounted to $1.5 million, a significant decrease of $11.6 million from a net loss of $13.1 million in the prior year. The operating expenses fell by $2.9 million compared to prior year and the adjusted EBITDA amounted to $1.5 million, an increase of $9.8 million from the year prior.

“Our impressive increase in revenue this quarter and incredible overall results for this year demonstrate a year of sustained growth and profitability, one which continued to drive our net income and adjusted EBITDA up,” said Zohar Krivorot, President & Chief Executive Officer of Cannara. “Our three flagship brands carved unique niches in the industry, offering handcrafted, hang-dried, slow-cured and hand-trimmed cannabis with the flower’s natural properties intact. The consumer response to these products outperformed even our expectations, as we saw a remarkable increase in both new and loyal customers embracing the dynamism of our product portfolio. We are also thrilled by the continued expansion of our Cannara family, as we increasingly rely on purpose-driven leaders whose talent for strategy shape the organization’s competencies. Over the course of the next fiscal, we are well-positioned for national growth and will continue to seek opportunities that support our mission, allocating efforts to existing and new activities.”

Looking Ahead

Cannara said it plans to optimize the additional debt financing from CIBC to finalize the redesign of several zones at the Valleyfield Facility in order to replicate the indoor cultivation environment, including growing without utilizing the sun and launching the operations at the site. The first 25,000 square foot zone was propagated with 9,600 plants in November 2021 and the next 25,000 square foot zone is planned to be propagated in January 2022. Cannara also stated that its existing cash resources of $8.2 million (as of August 31, 2021), along with the forecasted cash flows and financing that occurred subsequent to year-end, will enable it to fund its planned operating expenses for at least the next twelve months from August 31, 2021.

“Our tremendous growth was driven by strategic retail activities in Québec, combined with well-thought-out operational development investments, the cultivation and sale licenses of our two mega facilities, and the cannabis revenues generated during the second half of 2021,” said Nicholas Sosiak, Chief Financial Officer of Cannara. “The incredible performance, strong balance sheet, and increase in gross profit all underscore our long-term growth strategy and commitment to our customers, against the backdrop of strong demand for our products. As we continue to generate profitable growth and outsized returns, we will move forward from a position of financial strength and are ideally positioned to showcase continued positive Adjusted EBITDA.”

After the quarter and fiscal year ended, Cannara secured an additional bank credit amounting to $22 million increased from a previous loan of $5.4 million with Canadian Imperial Bank of Commerce, and expanded to the Ontario market. The company also launched two new hash products within the Nugz brand in Quebec retail stores; Old School Hash in a 3-gram bar and Ice Water Hash in a 1-gram temple ball.


StaffJuly 28, 2021
Cannara.jpg

4min00

Cannara Biotech Inc. (OTCQB: LOVFF) announced its third-quarter results for the period ending May 31, 2021, with total revenue of $7.2 million, including $5.9 million in cannabis sales, net of excise tax. this was a huge gain over last year’s $763,906. The net income for the company was $1.7 million versus last year’s net loss of $2.5 million.

“This quarter’s results are a testament to our strategy’s efficacy and management’s focus,” said Zohar Krivorot, President & Chief Executive Officer of Cannara. “With impressive revenue generation in our first full quarter of sales in retail market, the closing of our additional $5 million private placement, and headline acquisition of our latest one million square foot facility in Valleyfield, we are now positioned among the country’s leading cannabis producers.”

Cannara said it sold approximately 1,400 kg of cannabis it had in inventory from previous harvests for a total value of $1,265,000.

“Our positive net income and strong gross margins confirm our operational excellence, uniquely lean company structure, and continued growth,” said Nicholas Sosiak, Chief Financial Officer of Cannara. “Cannara’s core competence is our differentiated model that underscores our ability to excel at maximizing the use of our resources. We are executing against this proven model, as we continue to scale our business in the next chapter of our growth roadmap.”

Following the end of the quarter, Cannara acquired a one million sq. ft. state-of-the-art cultivation facility from The Green Organic Dutchman Ltd. (“TGOD”) for $27 million, providing it with the ability to reach an annual cultivation capacity of 125,000 kg of premium-grade cannabis. The company also launched an additional six SKUs in the market under the Tribal and Orchid CBD brands in June 2021 and released three new cannabis genetics, Cuban Linx, Do-Si-Dos, CBD Runtz, in dried flower and pre-roll formats

On the financial side, Cannara closed private placements of $24.3 million priced at a premium to the market price at the time of the transaction and $5.7 million in convertible debentures bearing interest at 4% to fund the acquisition of the Valleyfield facility and related working capital expenditures. It converted the company’s existing $5 million credit facilities bearing interest at 13% into a convertible debenture bearing 4% interest and subject to a statutory hold period of four months and one day from the date of issuance.

In addition, it uplisted to the TSX Venture (TSXV) from the Canadian Stock Exchange (CSE) on April 8, 2021, reflecting the company’s maturity and the commercialization of its operational strategy.


Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.